Focus on polypharmacy in schizophrenia: does anyone truly benefit?

Int J Neuropsychopharmacol. 2004 Jun;7(2):109-11. doi: 10.1017/S1461145704004183.
No abstract available

Publication types

  • Comment
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antipsychotic Agents / therapeutic use*
  • Dopamine D2 Receptor Antagonists
  • Drug Therapy, Combination
  • Humans
  • Schizophrenia / drug therapy*

Substances

  • Antipsychotic Agents
  • Dopamine D2 Receptor Antagonists